ライフサイエンスコーパス: B-cell receptor

1 nly one autosome expresses a functional T or B cell receptor.

2 tes as secreted antibodies or as part of the B-cell receptor.

3 red with MOG by MOG-specific B cells via the B-cell receptor.

4 ricted to rare B cells carrying HDM-specific B cell receptors.

5 g antibodies or bind particular Ig germ-line B-cell receptors.

6 pression of stereotyped IGHV4-39/IGKV1(D)-39 B-cell receptors.

7 l-like receptors, NOD-like receptors, T- and B-cell receptors.

8 ent to generate a large repertoire of T- and B-cell receptors.

9 igen accessibility by shielding antigen from B-cell receptor access.

10 Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2

11 f-function mutations that lead to autonomous B-cell-receptor activity.

12 GCs are required for almost all B-cell receptor affinity maturation and will be a critic

13 es surveyed the activation status of the pre-B cell receptor and comprehensively investigated downstr

14 ted weakly in response to activation via the B cell receptor and TLR9, indicating a B cell defect.

15 teractions such as that between glycosylated B cell receptors and lectins within the microenvironment

16 ase delta (PI3Kdelta), a linchpin in the pre-B-cell receptor and interleukin 7 receptor signaling pat

17 It inhibits signal transduction by the B-cell receptor and its coreceptor CD19.

18 n that were enriched for factors involved in B-cell receptor and JAK/STAT signaling, the nonclassical

19 or other BTK mutations, and other targets in B-cell receptor and MYD88 signaling.

20 cell lymphoma (MCL) cells exhibit increased B-cell receptor and nuclear factor (NF)-kappaB activitie

21 CR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future cl

22 erate on stimuli differently directed to the B-cell receptor and Toll-like receptor 9.

23 iation to immunoglobulin secreting IgM after B-cell receptor and Toll-like receptor triggering were s

24 sting that SpA cross-linking of VH3 idiotype B-cell receptors and activation via attached peptidoglyc

25 s provide the antigen recognition portion of B-cell receptors and derivative antibodies.

26 by pattern recognition receptors, T-cell and B-cell receptors and tumor necrosis factor receptors, an

27 itory activity that reduced T-cell receptor, B-cell receptor, and interferon signaling in B cells.

28 s encoding signaling components that mediate B cell receptor- and or cytokine receptor-mediated signa

29 rthermore, we find that PTIP is required for B cell receptor- and T:B interaction-induced proliferati

30 the 426c Env that activate germline-reverted B cell receptors are candidate immunogens for eliciting

31 We expressed the lymphoma B-cell receptors as soluble immunoglobulin Gs and membra

32 or survival via B-cell activating factor and B-cell receptor-associated pathways.

33 Here we aimed to target the B-cell receptor-associated protein CD79b by a T-cell rec

34 ne function, to the new agents targeting CLL B-cell receptor-associated signaling.

35 Such B cells experience both B cell receptor (BCR) activation and TLR engagement, lea

36 face receptor sialic acid (SA) to identify a B cell receptor (BCR) activation modality that proceeded

37 Diverse cellular signaling events, including B cell receptor (BCR) activation, are hypothesized to be

38 , much attention has been focused on the CLL B cell receptor (BCR) and on chemokine receptors that en

39 apidly phosphorylated downstream of both the B cell receptor (BCR) and the B cell-activating factor (

40 tein (WASp)-deficient B cells have increased B cell receptor (BCR) and Toll-like receptor (TLR) signa

41 At the pre-B cell receptor (BCR) checkpoint, developing pre-B cells

42 al capsids elicit antibody responses through B cell receptor (BCR) crosslinking in the absence of T c

43 to activate B cells expressing the germline B cell receptor (BCR) forms of anti-CD4-BS bNAbs.

44 emia (CLL) cells on signals derived from the B cell receptor (BCR) has encouraged the development of

45 Antigen binding to the B cell receptor (BCR) induces receptor clustering, cell

46 ng a Ubqln1(-/-) mouse strain, we found that B cell receptor (BCR) ligation of Ubqln1(-/-) B cells le

47 ted with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an importan

48 ovax 23 and had impaired selection of the B1 B cell receptor (BCR) repertoire.

49 Yet, infection of mice with limited B cell receptor (BCR) repertoires impaired the response,

50 ion work together to produce antibody-coding B cell receptor (BCR) sequences for a remarkable diversi

51 idelalisib, and dasatinib, drugs that block B cell receptor (BCR) signaling and are used in the trea

52 B cells in sIgM (-/-) mice display increased B cell receptor (BCR) signaling as judged by increased l

53 However, the role of Rictor on B cell receptor (BCR) signaling as well as the underlyin

54 Considering the central role of B cell receptor (BcR) signaling in CLL pathobiology, it

55 cell lines that are highly sensitive to the B cell receptor (BCR) signaling inhibitors ibrutinib and

56 express an array of inhibitory receptors and B cell receptor (BCR) signaling is stunted in atypical M

57 B cell receptor (BCR) signaling plays an important patho

58 Chronic active B cell receptor (BCR) signaling, a hallmark of the activ

59 e found that PDK1 deletion strongly impaired B cell receptor (BCR) signaling, but IL-4 costimulation

60 We discuss targeting of B cell receptor (BCR) signaling, with emphasis on identi

61 switch mechanism for NF-kappaB activation in B cell receptor (BCR) signaling.

62 oma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling.

63 71 and found that components of the proximal B cell receptor (BCR) signalosome were enriched within t

64 OB1 transnuclear B cells express an IgG1 B cell receptor (BCR) specific for ovalbumin (OVA), the

65 nts' B cells fail to activate NF-kappaB upon B cell receptor (BCR) stimulation.

66 functions, including those regulated by the B cell receptor (BCR) through increased cytosolic Ca(2+)

67 ectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR sign

68 , we have described a relationship among the B cell receptor (BCR), TLR9, and cytokine signals that r

69 ly restricted antigen-specific receptor, the B cell receptor (BCR), which allows the cell to recogniz

70 Nevertheless, recent work has shown that B cell receptor (BCR)-antigen engagement in vitro can pr

71 7 to the IgM on B cell surface activates the B cell receptor (BCR)-induced Ca(2+) signaling pathway a

72 The compounds inhibit B cell receptor (BCR)-mediated AKT phosphorylation (pAKT

73 beta) expression and correlatively inhibited B cell receptor (BCR)-mediated gammaherpesviral replicat

74 BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcga

75 B lymphocytes through the specificity of the B cell receptor (BCR).

76 evels of B-lineage transcription factors and B cell receptor (BCR)/pre-BCR-signaling genes.

77 hroughput sequencing of transcripts encoding B cell receptors (BCR-seq) to quantitatively determine t

78 ct of CD23 expression on the early events of B-cell receptor (BCR) activation using CD23 knockout (KO

79 Here, we demonstrate activation of B-cell receptor (BCR) and canonical NF-kappaB signaling

80 ients harbor mutations in the interconnected B-cell receptor (BCR) and CXCR4 signaling pathways.

81 man B lymphocytes, HVCN1 associates with the B-cell receptor (BCR) and is required for optimal BCR si

82 istically, we show that SPRY2 attenuates the B-cell receptor (BCR) and MAPK-Erk signaling by binding

83 CLL cells show prominent activation of both B-cell receptor (BCR) and NF-kappaB pathways.

84 Inhibitors of B-cell receptor (BCR) and pre-BCR signaling were success

85 lobulin V region genes encoding a functional B-cell receptor (BCR) are destined to die.

86 Kinase inhibitors targeting the B-cell receptor (BCR) are now prominent in the treatment

87 We demonstrate that dominant IgG4(+) B-cell receptor (BCR) clones determined by next-generati

88 and regulates B-cell signaling by modulating B-cell receptor (BCR) clustering and internalization.

89 inimally activated or anergic in response to B-cell receptor (BCR) crosslinking in vitro.

90 Such anergic cells are characterized by B-cell receptor (BCR) desensitization and altered downst

91 ssion of Ahr in B cells is up-regulated upon B-cell receptor (BCR) engagement and IL-4 treatment.

92 B-cell receptor (BCR) engagement with surface-tethered a

93 Antigenic stimulation via the B-cell receptor (BCR) is a major driver of the prolifera

94 However, the introduction of B-cell receptor (BCR) kinase inhibitors such as ibrutini

95 5-phosphatase 1 and were more responsive to B-cell receptor (BCR) ligation than CLL with low-level m

96 t membrane protein 2A (LMP2A) functions as a B-cell receptor (BCR) mimic known to provide survival si

97 Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in th

98 To investigate the effects of aging on B-cell receptor (BCR) repertoire evolution during an imm

99 - and light-chain genes results in a diverse B-cell receptor (BCR) repertoire including self-reactive

100 B-cell receptor (BCR) repertoire profiling is an importa

101 major costimulatory molecule for amplifying B-cell receptor (BCR) responses.

102 To address this in cGVHD, we studied B-cell receptor (BCR) responsiveness in 48 patients who

103 ion of spleen tyrosine kinase (SYK) in tonic B-cell receptor (BCR) signal-dependent diffuse large B-c

104 B-cell lymphoma is characterized by aberrant B-cell receptor (BCR) signaling and constitutive nuclear

105 ese B-ALLs encode proteins implicated in pre-B-cell receptor (BCR) signaling and migration/adhesion,

106 FL cells remain highly dependent on B-cell receptor (BCR) signaling and on a specific cell m

107 le BTK is inhibited, downstream mediators of B-cell receptor (BCR) signaling are activated in persist

108 HGAL protein also regulates B-cell receptor (BCR) signaling by directly binding to a

109 leukemia (CLL) and affects the threshold for B-cell receptor (BCR) signaling by repressing expression

110 B-cell receptor (BCR) signaling has emerged as essential

111 mediated genomic modification to investigate B-cell receptor (BCR) signaling in cell lines of diffuse

112 Targeting B-cell receptor (BCR) signaling in chronic lymphocytic l

113 ssue of Blood, Krysov et al demonstrate that B-cell receptor (BCR) signaling in chronic lymphocytic l

114 In this study, we used chronic active B-cell receptor (BCR) signaling in diffuse large B-cell

115 Recent studies revealed the importance of B-cell receptor (BCR) signaling in maintaining MCL survi

116 Our work also pinpoints the regulation of B-cell receptor (BCR) signaling in the release of CLL ex

117 Targeting B-cell receptor (BCR) signaling is a successful therapeu

118 Prolonged or uncontrolled B-cell receptor (BCR) signaling is associated with autoi

119 B-cell receptor (BCR) signaling is essential for the dev

120 Altered B-cell receptor (BCR) signaling might contribute to the

121 uggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, sign

122 sine kinase and PI3K inhibitors that inhibit B-cell receptor (BCR) signaling pathway at proximal kina

123 racterized by constitutive activation of the B-cell receptor (BCR) signaling pathway, but variable re

124 a covalent inhibitor of BTK, a member of the B-cell receptor (BCR) signaling pathway, which is critic

125 Inhibition of B-cell receptor (BCR) signaling pathways in chronic lymp

126 a niche and lead to activation of downstream B-cell receptor (BCR) signaling pathways.

127 B-cell receptor (BCR) signaling plays a key role in the

128 e CD21(low) B cells display defects in early B-cell receptor (BCR) signaling resembling those of aner

129 endothelial cell angiogenesis, regulation of B-cell receptor (BCR) signaling, and the survival, activ

130 inked to chronic infection, which may induce B-cell receptor (BCR) signaling, resulting in aberrant B

131 Agents targeting B-cell receptor (BCR) signaling-associated kinases such

132 ll lymphoma (DLBCL) relies on chronic active B-cell receptor (BCR) signaling.

133 the introduction of therapeutics that target B-cell receptor (BCR) signaling.

134 vation resulting from aberrant regulation of B-cell receptor (BCR) signaling.

135 volunteers, the balance between the CD40 and B-cell receptor (BCR) signalling modulated IL-10 product

136 The disease is believed to be driven by B-cell receptor (BCR) signals generated by external anti

137 ronic lymphocytic leukemia (CLL) cells after B-cell receptor (BCR) stimulation and show that current

138 ance of autonomous (exo-antigen-independent) B-cell receptor (BCR) stimulation in conjunction with li

139 er resistance to ABT-199 can be conferred by B-cell receptor (BCR) stimulation, which is another impo

140 inhibited the activation of Akt kinase upon B-cell receptor (BCR) stimulation.

141 mphocytic leukemia (CLL), stimulation of the B-cell receptor (BCR) triggers survival signals.

142 With expression of a functional pre-B-cell receptor (BCR), cytokine signaling is attenuated

143 ated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-lik

144 -surface product, the variable region of the B-cell receptor (BCR), otherwise known as idiotype.

145 nergy induced by continual engagement of the B-cell receptor (BCR), such as high expression of phosph

146 ells expressing the fully humanized gl3BNC60 B-cell receptor (BCR), we immunized mice carrying both t

147 IgH and IgL chains associate to form the B-cell receptor (BCR), which, upon antigen binding, acti

148 Mutations in genes promoting the tonic B-cell receptor (BCR)-->PI3K pathway (TCF3 and ID3) did

149 B-cell receptor (BCR)-activated B cells contribute to pa

150 Here, we show that on B-cell receptor (BCR)-mediated p70s6K activation, PDCD4

151 Cell-autonomous B-cell receptor (BcR)-mediated signalling is a hallmark

152 detail how PDE4 inhibition downmodulates the B-cell receptor (BCR)-related kinases spleen tyrosine ki

153 y CCC criteria, 6 of 8 DLBCL PDX models were B-cell receptor (BCR)-type tumors that exhibited selecti

154 imulation by restoring signaling through the B-cell receptor (BCR).

155 s initiated by the binding of antigen to the B-cell receptor (BCR).

156 Despite antigen engagement and intact B-cell-receptor (BCR) signaling, chronic lymphocytic leu

157 antibodies (sIg) or as membrane-bound (mIg) B cell receptors (BCRs) through alternative RNA splicing

158 B cell activation via B cell receptors (BCRs), a process requiring lipid rafts

159 trimers is virtually impenetrable for murine B cell receptors (BCRs).

160 rates preimmune Ig repertoires, expressed as B cell receptors (BCRs).

161 L patients have stereotyped antigen-specific B-cell receptors (BCRs) with a high level of sequence ho

162 ." These cells express antigen-specific T or B cell receptors, but behave with innate characteristics

163 tion of B cells carrying somatically mutated B-cell receptors by follicular helper T (TFH) cells in g

164 We show that FOXM1 levels peak at the pre-B-cell receptor checkpoint but are dispensable for norma

165 heir expression transiently peaks at the pre-B-cell receptor checkpoint.

166 r of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signal

167 CD19, a signaling component of the B cell receptor complex, is one of multiple regulators d

168 chains of immunoglobulin that determine the B cell receptor composition undergo stepwise rearrangeme

169 idylinositol (3,4,5)-trisphosphate (PIP3) on B cell receptor-containing early endosomes and proper so

170 ely by the B cell-specific pathway involving B cell receptor cross-linking.

171 nd TLR4 signaling, and partially rescued via B-cell receptor crosslinking.

172 PBs underwent affinity maturation, but their B cell receptors demonstrated significant bias toward th

173 and live cells, including Lyn kinase and the B-cell receptor during antigen stimulation.

174 The B-cell receptor enables individual B cells to identify d

175 ells and that the tumor microenvironment and B-cell receptor engagement are important.

176 ion elicits BTK-independent activation after B-cell receptor engagement, implying the formation of a

177 In A20 B cells transduced with TG2-specific B-cell receptor, epitope 2-expressing cells had poorer u

178 3'RR distal part, including hs4, fine-tuned B-cell receptor expression in newly formed and naive B-c

179 The IgH 3'RR plays a pivotal role in early B-cell receptor expression, germ-line transcription prec

180 e heavy chain variable region (Vh) 5 and Vh7 B-cell receptor families that harbor anti-PC reactivity.

181 Engagement of the B cell receptor for antigen (BCR) leads to immune respon

182 Inhibitors of the B-cell receptor for antigen signaling and antibodies aga

183 nopposed activation of B cells through their B-cell receptor for antigen, as seen in B cells lacking

184 B-cell receptors form ordered clusters to recruit kinase

185 ility of diverse Envs to engage the germline B cell receptor forms of known broadly neutralizing anti

186 used by defects in genes required for T- and B-cell receptor gene rearrangement.

187 These Mphi precursors have non-rearranged B-cell receptor genes and coexpress myeloid (GR1, CD11b,

188 complementarity determining region 3 of each B cell receptor heavy chain in every patient repertoire

189 in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3

190 By integrating B-cell receptor immunoglobulin stereotypy (for subsets 1

191 on of chronic lymphocytic leukaemia based on B-cell receptor immunoglobulin stereotypy improves the D

192 Although preliminary evidence suggests that B-cell receptor immunoglobulin stereotypy is relevant fr

193 ly assessed the clinical implications of CLL B-cell receptor immunoglobulin stereotypy, with a partic

194 r the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IG) has proved inst

195 ocytic leukaemia (CLL) carry quasi-identical B-cell receptor immunoglobulins and can be assigned to d

196 tion of PLCgamma2 activity serves to amplify B cell receptor-induced Ca(2+) signaling.

197 ronic lymphocytic leukemia cells, repressing B-cell receptor-induced Ca(2+) elevation and apoptosis.

198 Other B-cell receptor inhibitors, second-generation proteasome

199 , we transferred B cells with germline VRC01 B cell receptors into congenic recipients to elucidate t

200 s proliferation, such that engagement of the B-cell receptor is important for malignant progression.

201 nzyme in the signaling pathway downstream of B-cell receptor, is an effective treatment against many

202 These include B-cell receptor, JAK/STAT, NF-kappaB, NOTCH, and Toll-li

203 B-cell receptor kinase inhibitor (KI) therapy represents

204 th SLAMF6 only in association with clustered B-cell receptors likely recognizing self-antigens, sugge

205 BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the r

206 anisms of cytotoxic T cell killing, inhibits B cell receptor-mediated gammaherpesviral replication in

207 tions as a negative regulator and attenuates B-cell receptor-mediated calcium signaling.

208 -antigens, suggesting that SLAM/SAP regulate B-cell receptor-mediated central tolerance.

209 B-cell receptor-mediated degradation of BCL6 was reduced

210 We show linear ubiquitination at B-cell receptor microclusters and signalosomes.

211 B cells on selective in vitro stimulation of B-cell receptor or Toll-like receptor 9 pathways were re

212 Activation of the B cell receptor pathway activates lytic viral expression

213 or NFKBIZ amplification, frequent concurrent B-cell receptor pathway activation, and deregulation of

214 ndicated that the fibrils activated the CD40/B-cell receptor pathway in B-1a cells and induced a set

215 target of rapamycin signaling cascade, other B-cell receptor pathway inhibitors, Bcl-2 family inhibit

216 am of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ib

217 or Myb attenuated B cell action by altering B cell receptor pathways and MHCII cell surface presenta

218 for maintaining quiescence before precursor B cell receptor (pre-BCR) expression and for reestablish

219 Besides binding glycans, GAL1 is also a pre-B cell receptor (pre-BCR) ligand that induces receptor c

220 In developing B cells, pre-B cell receptor (pre-BCR) signals initiate immunoglobuli

221 ll precursor ALLs that differed by their pre-B cell receptor (pre-BCR) status were induced and displa

222 epigenetic landscape at Igk dictated by pre-B cell receptor (pre-BCR)-dependent Erk activation.

223 Expression of the pre-B-cell receptor (pre-BCR) by pre-BII cells constitutes a

224 The pre-B-cell receptor (pre-BCR) is an important checkpoint of

225 present in 5%-7% of pediatric and 50% of pre-B-cell receptor (preBCR(+)) acute lymphocytic leukemia (

226 Clonal diagnostic markers (eg, unique T- or B-cell receptor rearrangements) are not available for NK

227 of infiltrating immune cell types, the T or B cell receptor repertoire, and direct the design of a p

228 We reveal a highly similar B-cell receptor repertoire among the four main human IgM

229 also impacts the B-cell compartment and the B-cell receptor repertoire in patients not affected by M

230 hat the early PNOIT-induced Ara h 2-specific B-cell receptor repertoire is oligoclonal and somaticall

231 eration of a broad T-cell receptor (TCR) and B-cell receptor repertoire.

232 antigen-experienced and possess more diverse B-cell receptor repertoires compared to those of hypergl

233 , we have delineated the human serum IgG and B-cell receptor repertoires following tetanus toxoid (TT

234 rm longitudinal analyses of HIV Env-specific B-cell receptor responses to SHIV(AD8) infection and Env

235 Mutations that affect the pre-B-cell receptor result in early B-cell differentiation b

236 so interacted with B lymphocytes via the IgD B-cell receptor, resulting in internalization of bacteri

237 B cell receptor sequence diversity is generated by a ran

238 idden Markov Model (multi-HMM) framework for B cell receptor sequences.

239 apply the Haystack Heuristic to nine million B-cell receptor sequences obtained from nearly 100 indiv

240 We used high-throughput B cell receptor sequencing of plasma cells produced foll

241 B cell receptor signaling and downstream NF-kappaB activ

242 ate the expression of many components of the B cell receptor signaling pathway and the receptors for

243 n the CD40, JAK-STAT, Toll-like receptor and B cell receptor signaling pathways.

244 Inhibitors of B cell receptor signaling substantially changed the trea

245 protein, which mimics constitutively active B cell receptor signaling, is required for EBV-induced l

246 whether the EBV protein LMP2A, which mimics B cell receptor signaling, is required for EBV-induced l

247 lent to acute activation of autoreactive pre-B cell receptor signaling, which engaged a deletional ch

248 mediating energy metabolism, cell cycle, and B cell receptor signaling.

249 mbinations with inhibitors of chronic active B cell receptor signaling.

250 12/132) is induced in B cells in response to B cell receptor signaling.

251 gulation of genes involved in pathways, like B cell receptor signaling.

252 vel targeted therapies such as inhibitors of B-cell receptor signaling and B-cell lymphoma 2 have ope

253 or of Bruton tyrosine kinase (BTK), inhibits B-cell receptor signaling and is an effective, US Food a

254 inositol-3-kinase delta (PI3Kdelta) mediates B-cell receptor signaling and microenvironmental support

255 l-molecule inhibitors of kinases involved in B-cell receptor signaling are an important advance in ma

256 NK adaptor protein has a key role in the pre-B-cell receptor signaling cascade, as illustrated by the

257 controlled by constitutive activation of the B-cell receptor signaling component caspase recruitment

258 urbation of the tyrosine phosphosignature of B-cell receptor signaling components.

259 Although agents targeting B-cell receptor signaling have provided practice-changin

260 th rituximab, dexamethasone, bortezomib, and B-cell receptor signaling inhibitors, consistent with me

261 Constitutive B-cell receptor signaling leads to overexpression of the

262 ltage-gated proton channel-encoding gene and B-cell receptor signaling modulator, were associated wit

263 Newer oral B-cell receptor signaling pathway inhibitors are highly

264 ibrutinib, which targets the chronic active B-cell receptor signaling that characterizes ABC DLBCL.

265 or is proapoptotic in CLL cells and disrupts B-cell receptor signaling via BTK depletion.

266 se genes, which encode proteins that enhance B-cell receptor signaling, a putative CLL-growth/surviva

267 athways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling.

268 on's tyrosine kinase (BTK), is essential for B-cell receptor signaling, and most resistant cases carr

269 E controls an extended program that includes B-cell receptor signaling, cellular metabolism, and epig

270 ined favorably with multiple drugs targeting B-cell receptor signaling, one pathway that activates IK

271 c constitutively activated CD40 receptor and B-cell receptor signaling, respectively.

272 s function with the innate immune system and B-cell receptor signaling.

273 ed miR-28 targets involved in cell-cycle and B-cell receptor signaling.

274 ntly deleted and include LYN, a regulator of B-cell receptor signaling.

275 o dephosphorylation of kinases that regulate B-cell receptor signaling.

276 evelopment and function, and particularly in B-cell receptor signaling.

277 phosphorylation of proteins involved in the B-cell receptor signaling.

278 te the survival of B cells by mimicking host B-cell receptor signaling.

279 Combinatorial disruption of B-cell receptor signalling and PI3K-AKT-mTOR axis leads

280 NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk ki

281 IgM class B cell receptors specifically recognized the electrophil

282 ity is independent of CD4(+) T cell help and B cell receptor specificity and does not require B cell

283 ns were taken up by B cells independently of B-cell receptor specificity, indicating that HDM uptake

284 WASp-deficient B cells were hyperreactive to B cell receptor stimulation (BCR stimulation).

285 fically inhibits B cell responses induced by B cell receptor stimulation with antigen.

286 rvival and reestablished BTK activation upon B cell receptor stimulation.

287 gamma2 and its downstream pathways following B cell receptor stimulation.

288 ich refers to a state of unresponsiveness to B cell receptor stimulation.

289 and FOXP1 and the signaling potential of the B-cell receptor, thereby possibly accounting for the not

290 Moreover, SpA cross-links B-cell receptors to modify host adaptive immune response

291 (eNAMPT) is produced by CLL lymphocytes upon B-cell receptor, Toll-like receptor, and nuclear factor

292 pecific T and B lymphocytes using T cell and B cell receptor transgenic mice.

293 The B-cell receptor transmembrane activator and calcium modu

294 al cell receptor or gp42, which binds to the B-cell receptor, triggering gB-mediated fusion of the vi

295 Targeting of the B-cell receptor tyrosine kinases spleen tyrosine kinase,

296 The B cell receptor used in recognition can also be secreted

297 and single V-D, D-J gene combinations of the B-cell receptor variable region; increased frequency of

298 from IgH(MOG) mice that develop MOG-specific B cell receptors, we generated mixed chimeras together w

299 the context of immune receptors, such as the B cell receptor, where dysregulated signaling can result

300 k (DSB) repair is critical for generation of B-cell receptors, which are pre-requisite for B-cell pro